Weight Management of Dialysis Patients

Not Applicable

Not yet recruiting

• Conditions: Life Quality; Hypertension; Dry Weight; Hemodialysis; Interdialytic Weight Gain; Cardiovascular Events
• Interventions: Other: Routine care; Other: Family weight self-measurement and remote follow-up management based on wechat.

• Registration Number: NCT06333574
• Lead Sponsor: qinxiu zhang

Brief Summary

The goal of this clinical trial is to Improve the quality of life in Hemodialysis patient. The main questions it aims to answer are:

* \[Improve the self-compliance of dialysis patients with weight management\]

* \[alleviate the volume load of dialysis patients and reduce cardiovascular complications\] Participants will be divided into two groups based on a weight management regimen： Control group: received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient\'s weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.

Intervention group: On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients\' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-03
• Study First Submitted: 2024-03-13
• Study First Submitted QC: 2024-03-26
• Last Update Submitted: 2024-03-26
• Study First Posted: 2024-03-27
• Last Update Posted: 2024-03-27
• Study Start: 2024-04-01
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Age ≥18;
• Dialysis age ≥3 months;
• Survival ≥12 months;
• Patients themselves or family members can use wechat;
• Informed consent

Exclusion Criteria

• Have a cognitive or intellectual disability unable to read and understand SMS;
• Have mental illness;
• Other serious complications occurred

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	Routine care	received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
Intervention group	Family weight self-measurement and remote follow-up management based on wechat.	On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.

Primary Outcome Measures

Name	Time	Method
Adverse event rate	4, 8, and 12 weeks after intervention	incidence of cardiovascular events (or hospitalization rate due to cardiovascular events such as hypertension and heart failure)
Rate of completion	4, 8, and 12 weeks after intervention	Completion rate of home self-measured weight combined with wechat intervention(including completion rate of home self-measured weight, completion rate of wechat intervention, and combination completion rate）

Secondary Outcome Measures

Name	Time	Method
Laboratory index	4, 8, and 12 weeks after treatment	hemoglobin
level of PTH	4, 8, and 12 weeks after treatment
level of K	4, 8, and 12 weeks after treatment
level of Na	4, 8, and 12 weeks after treatment
concentration of albumin and prealbumin	4, 8, and 12 weeks after treatment
dialysis related symptoms	4, 8, and 12 weeks after treatment	(fatigue, weakness, pruritus, dialysis patient quality of Life scale)
level of Ga	4, 8, and 12 weeks after treatment	Laboratory index
level of P	4, 8, and 12 weeks after treatment
level of Cl	4, 8, and 12 weeks after treatment
Laboratory index of total protein	4, 8, and 12 weeks after treatment
Dialysis efficiency \ dialysis adequacy (KTV)	4, 8, and 12 weeks after treatment	Dialysis efficiency \\ dialysis adequacy (KTV)